Objective: To summarize the electroclinical characteristics of myoclonic atonic epilepsy (MAE) in children.

Method: The clinical data, video electroencephalogram (EEG) and simultaneous electromyography (EMG) of MAE patients were analyzed. The treatment and its effects were followed up.

Result: In 47 MAE patients, 25 had a history of febrile seizures (FS), 20 had a family history of FS or epilepsy. All patients had a normal development before the illness. The age of afebrile seizure onset was between 1.4 years to 5.8 years. The first seizure was generalized tonic-clonic seizure (GTCS) in 41 patients (87.2%). All patients had multiple seizure types, including 47 GTCS (97.9%), 34 myoclonic atonic seizures (72.3%), 47 myoclonic seizures (100%), 32 atonic seizures (68.1%), 36 atypical absences (76.6%) and 3 tonic seizures (6.4%). EEG backgrounds were slow or parietal θ rhythm, interictal EEG showed 1-4 Hz (predominant 2-3 Hz) generalized spike and wave or poly spike and wave discharges in all cases. Seizures were controlled by antiepileptic drugs (AEDs) in 41 patients (87.2%). Valproate was used in 37. Lamotrigine was used in 26. Mild mental retardation was observed in 10 children after the onset of the illness.

Conclusion: The clinical features of MAE included the following: the development was normal before the onset of the illness; the onset of seizure type was often GTCS. All patients had multiple generalized seizure types. Myoclonic atonic seizure was its characteristic seizure type. EEG showed generalized discharges. Early diagnosis and rational choice of AEDs are important for getting a better prognosis.

Download full-text PDF

Source

Publication Analysis

Top Keywords

myoclonic atonic
12
mae patients
8
seizure
8
gtcs patients
8
patients 872%
8
patients multiple
8
seizure types
8
atonic seizures
8
spike wave
8
seizure type
8

Similar Publications

Introduction: The effect of felbamate (FBM) on genetic generalized epilepsy (GGE) remains largely unknown. The utilization of FBM has been limited due to its potential risk of aplastic anemia and hepatic failure. This study aimed to comprehensively evaluate the efficacy and safety of FBM in the treatment of drug-resistant GGE.

View Article and Find Full Text PDF

Ketogenic diet therapy for the treatment of pediatric epilepsy.

Epileptic Disord

December 2024

Department of Neurology and Pediatrics, Johns Hopkins Hospital, Baltimore, Maryland, USA.

In 1921, the classic ketogenic diet was created at the Mayo Clinic in Rochester, Minnesota to treat epilepsy in children and adults. Over a century later, it is a widely used, standard-of-care therapy for typically treatment-resistant epilepsy worldwide. There are currently five versions of ketogenic diet therapy that can be started either in or out of the hospital setting.

View Article and Find Full Text PDF

Clinical, etiological, and therapeutic profile of early-onset absence seizures: A case series analysis.

Clin Neurol Neurosurg

December 2024

Pediatric Unit, Department of Medical and Surgical Sciences of Mothers, Children and Adults, University of Modena and Reggio Emilia, Modena 41121, Italy. Electronic address:

Typical absence seizures represent a distinctive form of epileptic activity typically observed in pediatric populations, predominantly manifesting between the ages of 4 and 10, constituting Childhood Absence Epilepsy (CAE). However, a subset of patients presents with Early-onset Absence Epilepsy (EOAE), characterized by seizure onset before the fourth year of life, often displaying favorable outcomes with antiseizure medication. Conversely, atypical absence seizures exhibit prolonged duration and frequently entail tonic, atonic, or myoclonic motor elements, suggesting a more severe clinical course, commonly associated with epileptic encephalopathies of childhood onset.

View Article and Find Full Text PDF

Evaluating the patient needs and tolerability of Clobazam liquid formulation (Likozam® 1 mg/mL): A French patient and care-givers' centered survey.

Epilepsy Behav

December 2024

Department of Pediatric Neurology, Reference Centre for Rare Epilepsies, Necker Enfants Malades University Hospital, AP-HP, Full Member of EPICARE European Reference Network for Rare and Complex Epilepsies, Université Paris Cité, Paris, France; Dravet Syndrome Alliance France, 3 Sent. Des Larris 45330, Le Malesherbois, France; Imagine Institute, Laboratory of Translational Research for Neurological Disorders, INSERM UMR 1163, Paris, France. Electronic address:

Article Synopsis
  • * A survey conducted among caregivers of patients with epilepsy, particularly Dravet syndrome, assessed experiences with different CLB formulations, including aspects like ease of swallowing and adaptability of doses.
  • * Out of 87 participants, the majority preferred the liquid form Likozam® for its ease of administration, highlighting its effectiveness for patients aged 2 to 41 years who often underwent polytherapy.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!